Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD22 CAR-T in CD19-Refractory Recurrent Lymphoma
NCT02721407Phase 1Unknown
- Sponsor
- Xinqiao Hospital
- Start
- Mar 2016
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL), sponsored by Xinqiao Hospital. Primary endpoint: Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0 at 4 weeks. Status: unknown.
02
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02721407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721407.